Pimecrolimus, yet another intriguing topical immunomodulator

Journal of Dermatological Treatment

Volumn 18, Issue 3, 2007, Pages 147-150

  Sehgal, Virendra N ^a   Pahwa, Manish ^b  

^a Sehgal Nursing Home   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Pimecrolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; BURNING SENSATION; CANCER RISK; DRUG FORMULATION; EAR INFECTION; ECZEMA; ERYTHEMA; FEVER; HUMAN; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; PHOTOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIASIS VULGARIS; RASH; RHINOPHARYNGITIS; SCABIES; SKIN DISEASE; TINEA; TREATMENT INDICATION; ULTRAVIOLET RADIATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS; DERMATITIS, ATOPIC; HUMANS; IMMUNOLOGIC FACTORS; TACROLIMUS;

EID: 34249775799     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701280642     Document Type: Article

References (35)

1. Sehgal VN, Srivastava G, Dogra S. Tacrolimus in dermatology: Pharmacokinetics, mechanism of action, drug interactions, dosages and side-effects. Part 1. Skinmed. In press.
2. Sehgal VN, Srivastava G, Dogra S. Tacrolimus: Approved and unapproved dermatologic indications/usages. Physician's Sequential Literature Survey. Part 2. Skinmed. In press.
3. Anonymous. First treatment for Hunter syndrome. FDA Consum. 2006;40:5.
4. Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat. 2005;16:149-53.
5. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: How much cause for concern? Br J Dermatol. 2005;153:701-5.
6. Fonacier L, Charlesworth EN, Spergel JM, Leung DM. The black box warning for topical calcineurin inhibitors: Looking outside the box. Ann Allergy Asthma Immunol. 2006;97:117-20.
7. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002;119:876-7.
8. Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, et al. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol. 1996;132:419-23.
9. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed. 2005;4:147-50.
10. Pock L, Svrckova M, Machackova R, Hercogova J. Pimecrolimus is effective in Fox-Fordyce disease. Int J Dermatol. 2006;45:1134-5.
11. Cedro M, Chaudhry S, Porter S. OC10 Topical pimecrolimus for the treatment of erosive oral lichen planus. Oral Dis. 2006;12:11.
12. Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J. 2006;12:7.
13. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30:191-5.
14. Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006;86:69-70.
15. De Almeida HL Jr, de Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosiva. Int J Dermatol. 2005;44:888-9.
16. Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005;44:1564-8.
17. Sarifakioglu E, Gumus II. Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: A prospective case series - a non-controlled, open-label study. J Dermatol Treat. 2006;17:276-8.
18. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006;4:942-6.
19. Djalilia HR, Memar O. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals. Laryngoscope. 2006;116:1809-12.
20. Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: A prospective case series. Br J Dermatol. 2005;153:390-4.
21. Schmook T, Kraft J, Benninghoff B, Roewert J, Ulrich C, Stockfleth E. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant. 2005;36:87-8.
22. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol. 2005;152:396-9.
23. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51:731-8.
24. Boms S, Gambichler T, Freitag M, Altmeyer P, Kreuterl A. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol. 2004;4:14.
25. Oskay T, Kaya Sezer H, Genç C, Kutluay L. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol. 2007;46:527-32.
26. Crawford KM, Bostrom P, Russ B, Boyd J. Pimecrolimus-induced tinea incognito. Skinmed. 2004;3:352-3.
27. Ruiz-Maldonado R. Pimecrolimus related crusted scabies in an infant. Pediatr Dermatol. 2006;23:299-300.
28. El Sayed F, Ammoury A, Dhaybi R, Bazex J. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol. 2006;54:548-50.
29. Ahn BK, Kim BD, Lee SJ, Lee SH. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol. 2005;52:532-3.
30. Narang T, Pahwa M, Kanwar AJ, Parsad D. Verruca vulgaris following treatment with tacrolimus ointment. Dermatology. 2006;213:254-5.
31. Saitta P, Brancaccio R. Allergic contact dermatitis to pimecrolimus. Contact Dermatitis. 2007;56:43-4.
32. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117:118-28.
33. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. Am Acad Dermatol. 2005;52:810-22.
34. Billich A, Aschauer H, Aszodi A, Stütz A. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29-35.
35. Ahn SJ, Oh SH, Chang SE, Choi JH, Koh JK. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. J Eur Acad Dermatol Venereol. 2006;20:1332-4.